Important Safety Information Full Prescribing
Information
ALOXI® Phase III Clinical Trials
Powerful CINV Prevention
That Can’t Be Ignored
Indication
In adults, ALOXI® (palonosetron HCl) injection 0.25 mg is indicated
for the prevention of acute and delayed nausea and vomiting associated with initial
and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting
associated with initial and repeat courses of highly emetogenic chemotherapy.
Important Safety Information
- Aloxi is contraindicated in patients known to have hypersensitivity to the drug
of any of its components
- Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting
include headache (9%) and constipation (5%)
For more information about ALOXI, please see Full Prescribing Information